Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.[2]
It was originally developed by Abgenix,[1] which was later acquired by Amgen.
References[edit]
|
|
|
Intracellular
(initiation) |
|
|
Intracellular
(reception) |
|
|
| Extracellular |
|
|
|
|
|
| Description |
|
|
| Disease |
|
|
| Treatment |
|
|
|
|
|
|
| Immune system ("-l(i[m])-") |
| Human ("-limu-") |
|
|
| Mouse ("-limo-") |
|
|
| Chimeric ("-lixi-") |
|
|
| Humanized ("-lizu-") |
|
|
Chimeric + humanized
("-lixizu-") |
|
|
|
| Interleukin ("-k(i[n])-") |
| Human ("-kinu-") |
|
|
| Humanized ("-kizu-", "-kinzu-") |
|
|
|
| Inflammatory lesions ("-les-") |
|
|
|
|
|
| Description |
|
|
| Disease |
|
|
| Treatment |
|
|
|
(what is this?) (verify)
